Nestlé Health Science Expands Portfolio with Acquisition of VOWST from Seres Therapeutics
Nestlé Health Science enhances its gastrointestinal product line by acquiring the global rights to VOWST.
In a strategic move to bolster its gastrointestinal health portfolio, Nestlé Health Science has acquired the global rights to VOWST, a promising fecal microbiota product, from Seres Therapeutics. This acquisition grants Nestlé exclusive rights to develop, commercialize, and manufacture VOWST worldwide. The product is specifically designed to prevent the recurrence of Clostridioides difficile infection in adults, a significant health concern. The agreement is pending customary regulatory approvals, including the green light from Seres' shareholders, highlighting Nestlé’s commitment to advancing healthcare solutions through strategic acquisitions.
For an in-depth look at this development, you can view the full article on Medical Dialogues.
Creativity is at the heart of what I do, backed by a lifetime of accolades in the arts and academics. This creative streak is complemented by my analytical abilities, making me a problem-solver who's always ready to tackle challenges.
More from Pharma News
All stories →
Bristol-Myers Squibb Gains FDA Accelerated Approval for Iberdomide in Relapsed or Refractory Multiple Myeloma
Eton Pharmaceuticals Gains FDA Fast Track for AMGLIDIA and Targets 2027 NDA with ASN-001 Acquisition
Discussion